Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

被引:317
作者
Mannweiler, Sebastian
Amersdorfer, Peter [1 ]
Trajanoski, Slave [2 ]
Terrett, Jonathan A. [3 ]
King, David [3 ]
Mehes, Gabor [1 ,4 ]
机构
[1] Oridis Biomed GMBH, A-8010 Graz, Austria
[2] Graz Univ Technol, Christian Doppler Lab Genom & Bioinformat, A-8010 Graz, Austria
[3] Medarex Inc, Milpitas, CA 95035 USA
[4] Univ Debrecen, Dept Pathol, H-4032 Debrecen, Hungary
关键词
Prostate cancer; Antibody; Immunohistochemistry; Therapy; CANCER; CELLS; ANTIBODIES;
D O I
10.1007/s12253-008-9104-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (< 10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
引用
收藏
页码:167 / 172
页数:6
相关论文
共 19 条
[1]   Technology Insight: monoclonal antibody imaging of prostate cancer [J].
Bander, NH .
NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (04) :216-225
[2]  
Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
[3]  
2-S
[4]   A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells [J].
Buehler, P. ;
Wolf, P. ;
Gierschner, D. ;
Schaber, I. ;
Katzenwadel, A. ;
Schultze-Seemann, W. ;
Wetterauer, U. ;
Tacke, M. ;
Swamy, M. ;
Schamel, W. W. A. ;
Elsaesser-Beile, U. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (01) :43-52
[5]  
Chang Sam S, 2004, Rev Urol, V6 Suppl 10, pS13
[6]  
Chang SS, 1999, CLIN CANCER RES, V5, P2674
[7]  
DOUGLAS G, 1990, ALTMAN PRACTICAL STA
[8]   A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer [J].
Elsaesser-Beile, Ursula ;
Wolf, Philipp ;
Gierschner, Dorothee ;
Buehler, Patrick ;
Schultze-Seemann, Wolfgang ;
Wetterauer, Ulrich .
PROSTATE, 2006, 66 (13) :1359-1370
[9]  
Gleason DF., 1977, UROLOGIC PATHOLOGY P, P171
[10]  
HOROSZEWICZ JS, 1987, ANTICANCER RES, V7, P927